These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK. Valentine WJ; Bottomley JM; Palmer AJ; Brändle M; Foos V; Williams R; Dormandy JA; Yates J; Tan MH; Massi-Benedetti M; Diabet Med; 2007 Sep; 24(9):982-1002. PubMed ID: 17593245 [TBL] [Abstract][Full Text] [Related]
44. The cost-effectiveness of transcatheter aortic valve implantation versus surgical aortic valve replacement in patients with severe aortic stenosis at high operative risk. Fairbairn TA; Meads DM; Hulme C; Mather AN; Plein S; Blackman DJ; Greenwood JP Heart; 2013 Jul; 99(13):914-20. PubMed ID: 23696198 [TBL] [Abstract][Full Text] [Related]
45. Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and -experienced United Kingdom patients in 2011. Simpson KN; Baran RW; Collomb D; Beck EJ; Van de Steen O; Dietz B J Med Econ; 2012; 15(4):796-806. PubMed ID: 22563716 [TBL] [Abstract][Full Text] [Related]
46. [Economic efficiency of renal denervation in patients with resistant hypertension: results of Markov modeling]. Kontsevaia AV; Suvorova EI; Khudiakov MB Kardiologiia; 2014; 54(1):41-7. PubMed ID: 24881310 [TBL] [Abstract][Full Text] [Related]
47. Telemonitoring and self-management in the control of hypertension (TASMINH2): a cost-effectiveness analysis. Kaambwa B; Bryan S; Jowett S; Mant J; Bray EP; Hobbs FD; Holder R; Jones MI; Little P; Williams B; McManus RJ Eur J Prev Cardiol; 2014 Dec; 21(12):1517-30. PubMed ID: 23990660 [TBL] [Abstract][Full Text] [Related]
48. Renal denervation for resistant hypertension: no. Taddei S; Dal Canto E; Bruno RM Intern Emerg Med; 2016 Jun; 11(4):495-8. PubMed ID: 27001888 [TBL] [Abstract][Full Text] [Related]
49. The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: a Markov decision analysis. Montgomery AA; Fahey T; Ben-Shlomo Y; Harding J J Hypertens; 2003 Sep; 21(9):1753-9. PubMed ID: 12923409 [TBL] [Abstract][Full Text] [Related]
50. Renal sympathetic denervation for treatment of hypertension: where are we now in 2019? Dasgupta I; Sharp ASP Curr Opin Nephrol Hypertens; 2019 Sep; 28(5):498-506. PubMed ID: 31268917 [TBL] [Abstract][Full Text] [Related]
51. Copeptin, resistant hypertension and renal sympathetic denervation. Schwerg M; Slagman A; Stangl K; Stangl V Biomarkers; 2017; 22(3-4):311-314. PubMed ID: 27775435 [TBL] [Abstract][Full Text] [Related]
52. Cost-effectiveness of treating resistant hypertension with an implantable carotid body stimulator. Young KC; Teeters JC; Benesch CG; Bisognano JD; Illig KA J Clin Hypertens (Greenwich); 2009 Oct; 11(10):555-63. PubMed ID: 19817936 [TBL] [Abstract][Full Text] [Related]
57. Dynamic treatment selection and modification for personalised blood pressure therapy using a Markov decision process model: a cost-effectiveness analysis. Choi SE; Brandeau ML; Basu S BMJ Open; 2017 Nov; 7(11):e018374. PubMed ID: 29146652 [TBL] [Abstract][Full Text] [Related]
58. Renal denervation for treatment of uncontrolled hypertension in an Asian population: results from the Global SYMPLICITY Registry in South Korea (GSR Korea). Kim BK; Böhm M; Mahfoud F; Mancia G; Park S; Hong MK; Kim HS; Park SJ; Park CG; Seung KB; Gwon HC; Choi DJ; Ahn TH; Kim CJ; Kwon HM; Esler M; Jang YS J Hum Hypertens; 2016 May; 30(5):315-21. PubMed ID: 26155994 [TBL] [Abstract][Full Text] [Related]
59. Long Term Cost-Effectiveness of a Systolic Blood Pressure Goal of <120 mmHg in Hypertensive Patients Without Diabetes Mellitus. Almalki ZS; Iqbal MS; Alablan FM; Alenazi RK; Tasha AR; Daghar MF; Aldossary NM Value Health Reg Issues; 2020 May; 21():157-163. PubMed ID: 31978689 [TBL] [Abstract][Full Text] [Related]